Events

Putting the Tech in Biotech Conference w/ Joanna Shields

Join our CEO, Joanna Shields, at the Morgan Stanley Putting the Tech in Biotech Conference

BenevolentAI’s CEO, will be at the Morgan Stanley Putting the Tech in Biotech Conference  in New York, on June 28, 2022.


Joanna Shields

CEO

Joanna joined BenevolentAI as CEO in 2018 and has accelerated its transformation from a startup to the clinical-stage, AI-enabled drug discovery company. She has a passion for creating responsible technology that benefits humanity, and has spent her professional life building companies, products and platforms that have transformed markets and reshaped industries. She has spent over three decades leading some of the world's best known technology companies, including Facebook, Bebo/Aol and Google. Prior to joining BenevolentAI, Joanna served in the UK Government as Under Secretary of State and Minister for Internet Safety & Security, Digital Economy Adviser, UK Ambassador for Digital Industries and Chair/CEO of TechCityUK. Joanna is the founder of the WeProtect Global Alliance, serves as the Co-Chair of the Global Partnership on Artificial Intelligence (GPAI) and is a Life Peer of the House of Lords.

More Posts

You Might Also Like

News
BenevolentAI announces participation in upcoming investor conferences
BenevolentAI announces its participation at two upcoming biotech and healthcare investor conferences hosted by Goldman Sachs and Morgan Stanley.
Jun 10, 2022
News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
Video
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022